|
| 37391056 | Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. | Clin Gastroenterol Hepatol | 2024 |
| 38096402 | Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. | J Crohns Colitis | 2024 |
| 38095692 | Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study. | Am J Gastroenterol | 2024 |
| 35245701 | Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data. | Clin Gastroenterol Hepatol | 2023 |
| 37636008 | Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies. | Crohns Colitis 360 | 2023 |
| 37962770 | Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease. | J Patient Rep Outcomes | 2023 |
| 35704691 | A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. | Inflamm Bowel Dis | 2023 |
| 35644340 | Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. | Clin Gastroenterol Hepatol | 2023 |
| 37323059 | A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. | Aliment Pharmacol Ther | 2023 |
| 36986672 | The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients. | Pharmaceutics | 2023 |
| 37379135 | Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. | N Engl J Med | 2023 |
| 37308036 | Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study. | Clin Gastroenterol Hepatol | 2023 |
| 36993763 | A Living Organoid Biobank of Crohn's Disease Patients Reveals Molecular Subtypes for Personalized Therapeutics. | bioRxiv | 2023 |
| 36623678 | Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. | Clin Gastroenterol Hepatol | 2023 |
| 36881820 | Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study. | Clin Transl Gastroenterol | 2023 |
| 36871574 | Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. | Lancet | 2023 |
| 36738762 | Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. | Lancet Gastroenterol Hepatol | 2023 |
| 36662860 | A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy. | Sci Adv | 2023 |
| 36067821 | Reply. | Gastroenterology | 2023 |
| 36240801 | Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. | Lancet Gastroenterol Hepatol | 2023 |
| 36124702 | Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme. | J Crohns Colitis | 2023 |
| 36191274 | The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. | Am J Gastroenterol | 2023 |
| 36006011 | Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study. | J Crohns Colitis | 2023 |
| 36343846 | Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study. | Clin Gastroenterol Hepatol | 2023 |
| 36113491 | Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. | Am J Gastroenterol | 2023 |
| 32950748 | Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. | Clin Gastroenterol Hepatol | 2022 |
| 35380740 | Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. | Clin Pharmacol Ther | 2022 |
| 35474325 | Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. | Aliment Pharmacol Ther | 2022 |
| 35798022 | Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. | Lancet Gastroenterol Hepatol | 2022 |
| 35644166 | Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. | Lancet | 2022 |
| 35644154 | Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. | Lancet | 2022 |
| 35644155 | Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. | Lancet | 2022 |
| 35788348 | CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. | Gastroenterology | 2022 |
| 36506749 | Modified Mayo score <i>versus</i> Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. | Therap Adv Gastroenterol | 2022 |
| 36075249 | ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. | Lancet Gastroenterol Hepatol | 2022 |
| 35973139 | Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. | Am J Gastroenterol | 2022 |
| 35905414 | Simplified Machine Learning Models Can Accurately Identify High-Need High-Cost Patients With Inflammatory Bowel Disease. | Clin Transl Gastroenterol | 2022 |
| 35963369 | Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. | Gastroenterology | 2022 |
| 36150926 | Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. | Clin Ther | 2022 |
| 33684552 | Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. | Clin Gastroenterol Hepatol | 2022 |
| 33766910 | Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). | Gut | 2022 |
| 33819666 | Advances in the Comprehensive Management of Postoperative Crohn's Disease. | Clin Gastroenterol Hepatol | 2022 |
| 33618023 | Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. | Clin Gastroenterol Hepatol | 2022 |
| 33640480 | Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. | Clin Gastroenterol Hepatol | 2022 |
| 33556578 | Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. | Clin Gastroenterol Hepatol | 2022 |
| 35227777 | Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. | Gastroenterology | 2022 |
| 35288651 | Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease. | Commun Biol | 2022 |
| 35189386 | IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. | Clin Gastroenterol Hepatol | 2022 |
| 35014040 | Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. | Aliment Pharmacol Ther | 2022 |
| 34951696 | A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. | BioDrugs | 2022 |